Ardelyx, Inc.NASDAQ: ARDX

Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

· Issued by Ardelyx, Inc. via GlobeNewswire

Summary by 6ix AI

Ardelyx, a commercial-stage biopharmaceutical company, is presenting results from a real-world analysis at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting. The analysis showed that gastrointestinal-related healthcare use fell after adults with irritable bowel syndrome with constipation (IBS-C) started IBSRELA (tenapanor).

Key details

  • The analysis was retrospective and observational, meaning it looked back at existing records. It covered 470 patients with IBS-C who started tenapanor at a national gastroenterology practice.
  • The median number of GI-related healthcare visits went from 4.5 in the year before starting tenapanor to 3.0 in the year after starting it.
  • Ardelyx is also presenting data on how the burden of IBS-C symptoms affects quality of life.
  • Ardelyx is also presenting the design and rationale of an ongoing Phase 3 (late-stage) study of tenapanor in adults with chronic idiopathic constipation (CIC), which is long-term constipation without a known cause.

What’s still pending

  • The Phase 3 study of tenapanor in chronic idiopathic constipation is ongoing.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/ardelyx-presents-real-world-data-at-acg-2026-showing-reduced-healthcare-resource-utilization-following-ibsrelar-initiation-in-adults-with-ibs-c-1

Watch Ardelyx's latest callArdelyx (NASDAQ:ARDX) Q2 2026 Earnings Call · Replay · Aug 6Read the transcript of Ardelyx (NASDAQ:ARDX) Q2 2026 Earnings Call

Additional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of life

WALTHAM, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from a real-world analysis being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting showing that gastrointestinal-related healthcare resource utilization (GI-HCRU) dropped significantly after adults with irritable bowel syndrome with constipation (IBS-C) started IBSRELA® (tenapanor). Ardelyx will also present data on how IBS-C symptom burden affects quality of life, along with the design and rationale of an ongoing Phase 3 study evaluating tenapanor in adults with chronic idiopathic constipation (CIC).

"IBS-C can affect patients in ways that extend well beyond their symptoms, placing a significant burden on daily life and quality of life, including through ongoing interactions with the healthcare system. We are encouraged by these real-world findings, which show a significant reduction in GI-related healthcare utilization following IBSRELA initiation," said Rajani Dinavahi, MD, Chief Medical Officer of Ardelyx. "Together with our additional data presented at ACG, these findings reflect our commitment to generating evidence that deepens our understanding of constipation-related disorders, helps inform patient care, and supports continued research into the potential role of tenapanor beyond IBS-C."

The data comes from a retrospective, observational real-world analysis of 470 patients with IBS-C who started tenapanor at a national gastroenterology practice. A significant reduction in median GI-related HCRU was observed, from 4.5 visits in the year before tenapanor initiation to 3.0 visits in the year following initiation (3.0 [IQR: 1, 6] vs. 4.5 [IQR: 2, 9]; P

Ardelyx, Inc. on 6ix

Story so far

Earlier from Ardelyx

All Ardelyx news releases